All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0/M1A/M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), ipilimumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.19 [1.00; 1.42]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.22; 2.06]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.82 [1.39; 2.38]
CheckMate 069 (all population), 2015 (REV) 1.35 [0.79; 2.31]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.69 [0.22; 2.17]
CheckMate 238, 2017 0.87 [0.66; 1.14]
EORTC 18071, 2015 0.72 [0.58; 0.89]
KEYNOTE-006 (2 week), 2015 (REV) 1.59 [1.19; 2.11]
KEYNOTE-006 (3 week), 2015 (REV) 1.45 [1.10; 1.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.96 [0.77; 1.20]
MDX010 Ipi vs gp100, 2010 0.66 [0.51; 0.86]
1.13 [0.91 ; 1.40 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 11 85% 5,944 low low deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.59 [1.31; 1.92]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.92 [1.56; 2.37]
EORTC 18071, 2015 0.73 [0.64; 0.83]
KEYNOTE-006 (2 week), 2015 (REV) 1.47 [1.15; 1.88]
KEYNOTE-006 (3 week), 2015 (REV) 1.47 [1.15; 1.87]
1.36 [0.90 ; 2.06 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 5 96% 3,323 low serious MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
EORTC 18071, 2015 0.76 [0.63; 0.91]
0.75 [0.65 ; 0.87 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,686 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.89 [1.56; 2.28]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.97; 2.87]
CheckMate 069 (all population), 2015 (REV) 2.78 [1.74; 4.43]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.14 [0.44; 10.39]
KEYNOTE-006 (2 week), 2015 (REV) 1.64 [1.34; 2.01]
KEYNOTE-006 (3 week), 2015 (REV) 1.64 [1.34; 2.01]
1.94 [1.64 ; 2.29 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 59% 2,547 low not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.12 [0.83; 1.52]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.75 [1.32; 2.33]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.76; 3.23]
CheckMate 069 (all population), 2015 (REV) 2.63 [1.59; 4.36]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.63 [1.02; 6.79]
CheckMate 069 (BRAF wild type), 2015 (REV) 2.50 [1.45; 4.30]
KEYNOTE-006 (2 week), 2015 (REV) 1.72 [1.38; 2.16]
KEYNOTE-006 (3 week), 2015 (REV) 1.72 [1.39; 2.13]
1.84 [1.53 ; 2.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 8 58% 3,383 low not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.73 [0.65 ; 0.83 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.72 [0.62 ; 0.82 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.84 [0.61; 1.16]
0.84 [0.61 ; 1.16 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 727 NA not evaluable objective responses (ORR)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.76 [0.50; 1.17]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.29 [0.17; 0.49]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.10; 0.28]
CheckMate 069 (all population), 2015 (REV) 0.07 [0.04; 0.12]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.21]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29]
KEYNOTE-006 (2 week), 2015 (REV) 0.27 [0.17; 0.41]
KEYNOTE-006 (3 week), 2015 (REV) 0.28 [0.18; 0.43]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 2.03 [1.03; 4.02]
MDX010 Ipi vs gp100, 2010 8.24 [1.85; 36.76]
0.35 [0.18 ; 0.69 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 91% 4,196 low low objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.28 [0.20; 0.41]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.11; 0.23]
CheckMate 069 (all population), 2015 (REV) 0.08 [0.03; 0.23]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.20]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29]
0.16 [0.09 ; 0.27 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV) 5 60% 1,544 low not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
EORTC 18071, 2015 7.53 [3.17; 17.90]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.51 [0.14; 1.83]
MDX010 Ipi vs gp100, 2010 0.99 [0.24; 4.05]
1.21 [0.28 ; 5.25 ] CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 4 86% 2,624 low not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
EORTC 18071, 2015 0.11 [0.08; 0.17]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.01 [0.68; 1.51]
MDX010 Ipi vs gp100, 2010 0.95 [0.59; 1.55]
0.42 [0.16 ; 1.10 ] CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 4 96% 2,624 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
0.15 [0.10 ; 0.21 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
0.11 [0.07 ; 0.18 ] CheckMate 238, 2017 1 0% 905 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 (REV) 1.49 [0.92; 2.42]
KEYNOTE-006 (3 week), 2015 (REV) 1.59 [0.97; 2.60]
1.54 [1.09 ; 2.17 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.08 [0.07 ; 17.38 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.42 [0.31; 0.57]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.99 [0.63; 1.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.27 [0.14; 0.51]
CheckMate 069 (all population), 2015 (REV) 1.33 [0.34; 5.28]
CheckMate 238, 2017 0.25 [0.15; 0.43]
EORTC 18071, 2015 14.40 [10.07; 20.60]
KEYNOTE-006 (2 week), 2015 (REV) 0.62 [0.41; 0.93]
KEYNOTE-006 (3 week), 2015 (REV) 0.86 [0.58; 1.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.50 [0.29; 0.86]
MDX010 Ipi vs gp100, 2010 1.09 [0.60; 1.98]
0.83 [0.35 ; 1.95 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 97% 5,805 low low TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.37 [0.25; 0.54]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.97; 2.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.26 [0.19; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.26 [0.12; 0.58]
CheckMate 238, 2017 0.20 [0.14; 0.27]
EORTC 18071, 2015 25.27 [14.14; 45.18]
KEYNOTE-006 (2 week), 2015 (REV) 1.19 [0.77; 1.85]
KEYNOTE-006 (3 week), 2015 (REV) 1.22 [0.78; 1.90]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.86 [0.50; 1.48]
MDX010 Ipi vs gp100, 2010 1.41 [0.69; 2.88]
0.89 [0.40 ; 1.94 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 97% 5,805 low low TRAE leading to death (grade 5)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.09; 2.75]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 238, 2017 0.25 [0.01; 5.55]
EORTC 18071, 2015 10.16 [0.55; 186.52]
KEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.83 [0.28 ; 2.46 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 7 0% 4,891 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.51 [0.36; 0.72]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.40 [0.88; 2.21]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.17; 0.37]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.10; 0.57]
CheckMate 069 (BRAF wild type), 2015 (REV) 0.30 [0.12; 0.71]
CheckMate 238, 2017 0.12 [0.08; 0.17]
EORTC 18071, 2015 21.35 [13.41; 33.97]
KEYNOTE-006 (2 week), 2015 (REV) 1.35 [0.71; 2.53]
KEYNOTE-006 (3 week), 2015 (REV) 0.81 [0.46; 1.44]
0.69 [0.24 ; 2.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 9 98% 5,139 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.44 [0.30; 0.66]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.93 [1.14; 3.27]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.37 [0.25; 0.55]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.09; 0.63]
CheckMate 238, 2017 0.09 [0.05; 0.15]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.40 [0.17 ; 0.98 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 7 91% 4,086 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 4.16 [0.14; 126.20]
CheckMate 238, 2017 0.50 [0.02; 14.96]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.80 [0.48 ; 6.69 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 4.23 [0.37; 47.88]
CheckMate 238, 2017 0.50 [0.09; 2.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.72 [0.03; 16.16]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.59 [0.24 ; 1.50 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 7 0% 3,793 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.08 [0.07 ; 17.38 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.05; 6.00]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
0.86 [0.12 ; 6.13 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
CheckMate 238, 2017 0.50 [0.05; 5.53]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.62 [0.16 ; 2.37 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
CheckMate 238, 2017 0.25 [0.03; 2.24]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.20; 24.20]
KEYNOTE-006 (3 week), 2015 (REV) 4.35 [0.20; 97.02]
1.38 [0.48 ; 3.97 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.34 [0.14 ; 12.95 ] CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 3 0% 1,207 moderate not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.46 [0.21; 1.04]
CheckMate 067 (N vs I ; all population), 2015 (REV) 8.64 [2.57; 29.01]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.92 [0.52; 1.65]
CheckMate 069 (all population), 2015 (REV) 0.34 [0.09; 1.23]
EORTC 18071, 2015 39.14 [5.34; 286.74]
KEYNOTE-006 (2 week), 2015 (REV) 5.18 [1.73; 15.52]
KEYNOTE-006 (3 week), 2015 (REV) 2.92 [1.20; 7.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.73 [0.67; 4.49]
MDX010 Ipi vs gp100, 2010 14.85 [0.83; 264.38]
2.35 [1.02 ; 5.42 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 9 82% 4,900 low serious Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.06 [0.12 ; 9.12 ] CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 3 0% 1,207 moderate not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.64 [0.10 ; 3.99 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 4 0% 2,315 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.03; 2.24]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.71 [0.17 ; 2.95 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 5 0% 2,455 low serious Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
KEYNOTE-006 (3 week), 2015 (REV) 0.54 [0.02; 16.17]
1.04 [0.09 ; 11.51 ] CheckMate 238, 2017, KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,438 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.54 [0.31; 0.95]
CheckMate 067 (N vs I ; all population), 2015 (REV) 2.08 [0.92; 4.69]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.60 [0.33; 1.11]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.33; 3.19]
CheckMate 238, 2017 0.15 [0.07; 0.34]
EORTC 18071, 2015 25.54 [6.16; 105.87]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.38; 3.15]
KEYNOTE-006 (3 week), 2015 (REV) 2.57 [0.66; 10.04]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.25 [0.47; 3.34]
MDX010 Ipi vs gp100, 2010 6.29 [0.75; 52.98]
1.28 [0.62 ; 2.67 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 84% 5,805 low critical Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.73 [0.33; 1.61]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.76 [0.36 ; 1.61 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 4 0% 2,315 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40]
0.56 [0.14 ; 2.24 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 5 0% 2,455 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.43 [0.19; 1.01]
CheckMate 069 (all population), 2015 (REV) 0.81 [0.15; 4.34]
EORTC 18071, 2015 42.70 [5.84; 312.15]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 3.73 [0.99; 14.11]
MDX010 Ipi vs gp100, 2010 10.44 [0.56; 193.00]
2.98 [0.56 ; 15.74 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 069 (all population), 2015 (REV), EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 5 83% 2,585 low not evaluable Eye disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.20; 5.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.22 [0.06; 0.80]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
CheckMate 238, 2017 0.50 [0.09; 2.74]
KEYNOTE-006 (2 week), 2015 (REV) 3.28 [0.34; 31.78]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.22; 5.41]
0.61 [0.28 ; 1.33 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 16% 3,360 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.55 [0.34; 0.88]
CheckMate 069 (all population), 2015 (REV) 0.45 [0.16; 1.29]
CheckMate 238, 2017 0.10 [0.05; 0.20]
EORTC 18071, 2015 22.61 [8.20; 62.34]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.34 [0.62; 2.92]
MDX010 Ipi vs gp100, 2010 10.83 [1.37; 85.84]
1.28 [0.31 ; 5.21 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 6 94% 3,490 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.51 [0.02; 11.44]
CheckMate 238, 2017 0.14 [0.02; 1.15]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.46 [0.14 ; 1.49 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low serious Hepatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.40 [0.08; 2.07]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.01; 1.82]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
KEYNOTE-006 (2 week), 2015 (REV) 0.36 [0.04; 3.48]
KEYNOTE-006 (3 week), 2015 (REV) 0.21 [0.02; 1.84]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.45 [0.05; 43.54]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.37 [0.15 ; 0.90 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 8 0% 3,955 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 0.06 [0.00; 1.08]
CheckMate 238, 2017 0.15 [0.07; 0.32]
EORTC 18071, 2015 57.44 [7.90; 417.44]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.36 [0.02; 6.86]
MDX010 Ipi vs gp100, 2010 0.16 [0.01; 3.32]
0.53 [0.04 ; 7.00 ] CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 5 87% 2,764 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.17 [0.01; 3.33]
CheckMate 238, 2017 2.01 [0.07; 59.97]
0.51 [0.04 ; 5.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 238, 2017 2 14% 1,631 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
CheckMate 238, 2017 1.00 [0.06; 16.07]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
0.97 [0.25 ; 3.75 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.70 [0.26; 1.85]
CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.29; 3.51]
CheckMate 069 (all population), 2015 (REV) 2.09 [0.29; 15.34]
CheckMate 238, 2017 0.18 [0.04; 0.81]
EORTC 18071, 2015 44.19 [2.67; 732.31]
KEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 2.93 [0.41; 21.02]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
1.67 [0.72 ; 3.91 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 50% 5,805 low critical Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
CheckMate 238, 2017 0.50 [0.05; 5.53]
KEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.45 [0.05; 43.54]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.77 [0.25 ; 2.38 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 9 0% 4,860 low serious Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.02; 0.99]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.67 [0.11; 4.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.02; 0.43]
CheckMate 069 (all population), 2015 (REV) 0.14 [0.01; 2.46]
CheckMate 238, 2017 0.10 [0.02; 0.44]
KEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.45 [0.05; 43.54]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.33 [0.13 ; 0.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 9 36% 4,860 low serious Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.16 [0.04; 0.73]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.26 [0.34; 4.75]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.07; 0.46]
CheckMate 069 (all population), 2015 (REV) 0.09 [0.01; 1.62]
CheckMate 238, 2017 0.18 [0.07; 0.48]
KEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.72 [0.03; 16.16]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.38 [0.17 ; 0.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 9 44% 4,860 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.86 [0.39; 1.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.17; 0.65]
CheckMate 069 (all population), 2015 (REV) 0.24 [0.03; 1.97]
0.48 [0.26 ; 0.88 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV) 4 19% 2,114 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
CheckMate 238, 2017 0.05 [0.00; 0.95]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40]
0.35 [0.12 ; 0.98 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 7 0% 4,086 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.07; 17.46]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
1.01 [0.23 ; 4.46 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 5 0% 2,455 low not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.08 [0.07 ; 17.38 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 4.05 [0.18; 90.07]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.28 [0.06; 1.37]
CheckMate 069 (all population), 2015 (REV) 2.07 [0.13; 33.80]
CheckMate 238, 2017 2.01 [0.07; 59.97]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.79 [0.27 ; 2.35 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low serious Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
2.17 [0.20 ; 24.03 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
EORTC 18071, 2015 18.45 [1.07; 319.15]
1.54 [0.01 ; 206.07 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), EORTC 18071, 2015 2 83% 1,671 low not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.08 [0.07 ; 17.38 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
2.17 [0.20 ; 24.03 ] KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 2 0% 1,067 moderate not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
0.50 [0.02 ; 15.01 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.25 [0.01; 5.57]
0.25 [0.01 ; 5.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.03; 3.22]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.09; 11.57]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40]
0.64 [0.21 ; 1.92 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,181 low not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
2.01 [0.07 ; 60.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.33 [0.28 ; 6.35 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,181 low not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 1.01 [0.14; 7.18]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
CheckMate 238, 2017 0.10 [0.01; 1.82]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.45 [0.05; 43.54]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.57 [0.22 ; 1.47 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 9 0% 4,860 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56]
CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80]
CheckMate 238, 2017 0.25 [0.01; 5.55]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.60 [0.16 ; 2.16 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 6 0% 3,360 low not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.40 [0.08; 2.07]
CheckMate 067 (N vs I ; all population), 2015 (REV) 5.10 [0.59; 43.89]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.17; 1.47]
CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66]
CheckMate 238, 2017 0.35 [0.13; 0.98]
EORTC 18071, 2015 10.16 [0.55; 186.52]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.58 [0.07; 4.98]
MDX010 Ipi vs gp100, 2010 2.02 [0.07; 60.83]
0.64 [0.34 ; 1.22 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 10 10% 5,805 low low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
CheckMate 238, 2017 1.00 [0.02; 50.62]
1.01 [0.08 ; 13.30 ] CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017 2 0% 1,045 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.12 [0.01; 2.36]
CheckMate 069 (all population), 2015 (REV) 0.67 [0.07; 6.66]
CheckMate 238, 2017 0.12 [0.01; 2.36]
0.27 [0.06 ; 1.25 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017 3 0% 1,771 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.71 [0.22; 2.27]
CheckMate 069 (all population), 2015 (REV) 0.10 [0.01; 1.83]
CheckMate 238, 2017 0.18 [0.07; 0.46]
EORTC 18071, 2015 42.00 [2.53; 697.02]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.64 [0.14; 3.00]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
0.80 [0.21 ; 3.02 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 6 71% 3,490 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 0.50 [0.02; 15.01]
CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
0.61 [0.08 ; 4.71 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV) 3 0% 1,974 low not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV) 2.01 [0.07; 60.22]
KEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
1.39 [0.16 ; 11.91 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 3 0% 1,793 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88]
CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 2.91 [0.06; 147.31]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.18 [0.22 ; 6.46 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 5 0% 2,162 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 1.01 [0.06; 16.16]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 0.14 [0.02; 1.15]
CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03]
KEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23]
KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74]
0.44 [0.12 ; 1.61 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 5 0% 2,455 low serious Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
CheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32]
KEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16]
KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92]
2.09 [0.38 ; 11.45 ] CheckMate 067 (N vs I ; all population), 2015 (REV), CheckMate 067 (NI vs I ; all population), 2015 (REV), KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV) 4 0% 2,315 low not evaluable Abdominal pain AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.17]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.97 [0.19; 4.85]
MDX010 Ipi vs gp100, 2010 0.28 [0.06; 1.36]
0.21 [0.03 ; 1.36 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 77% 1,719 low not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.06 [0.33; 3.38]
MDX010 Ipi vs gp100, 2010 0.35 [0.11; 1.12]
0.61 [0.20 ; 1.81 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 2 43% 774 low not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Constipation AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 2.95 [0.59; 14.78]
MDX010 Ipi vs gp100, 2010 3.07 [0.32; 29.91]
2.99 [0.80 ; 11.14 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 2 0% 774 low not evaluable Cough AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.15]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.45 [0.05; 43.54]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.20 [0.01 ; 6.38 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 69% 1,719 low not evaluable Decreased appetite AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.01; 0.46]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.97 [0.19; 4.85]
MDX010 Ipi vs gp100, 2010 0.50 [0.09; 2.76]
0.34 [0.07 ; 1.59 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 56% 1,719 low not evaluable Diarrhoea AE (grade 3-4)detailed results EORTC 18071, 2015 0.26 [0.18; 0.37]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.21 [0.49; 2.98]
MDX010 Ipi vs gp100, 2010 7.40 [0.90; 60.98]
1.01 [0.20 ; 5.07 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 89% 1,719 low not evaluable Dyspnoea AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.04 [0.37; 2.94]
MDX010 Ipi vs gp100, 2010 0.83 [0.25; 2.80]
0.95 [0.43 ; 2.08 ] MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 2 0% 774 low not evaluable Fatigue AE (grade 3-4)detailed results EORTC 18071, 2015 0.05 [0.03; 0.10]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.40 [0.62; 3.18]
MDX010 Ipi vs gp100, 2010 2.36 [0.71; 7.87]
0.53 [0.04 ; 6.96 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 96% 1,719 low not evaluable Headache AE (grade 3-4)detailed results EORTC 18071, 2015 0.04 [0.01; 0.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 2.20 [0.49; 9.98]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
0.42 [0.03 ; 6.30 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 92% 1,719 low not evaluable Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results EORTC 18071, 2015 0.80 [0.45; 1.45]
0.80 [0.45 ; 1.45 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increased ALT AE (grade 3-4)detailed results EORTC 18071, 2015 0.97 [0.55; 1.70]
0.97 [0.55 ; 1.70 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Nausea AE (grade 3-4)detailed results EORTC 18071, 2015 0.01 [0.00; 0.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 1.46 [0.36; 5.93]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
0.26 [0.02 ; 4.55 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 89% 1,719 low not evaluable Pruritus AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.07; 0.26]
0.14 [0.07 ; 0.26 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Pyrexia AE (grade 3-4)detailed results EORTC 18071, 2015 0.21 [0.08; 0.56]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV) 0.72 [0.03; 16.16]
MDX010 Ipi vs gp100, 2010 0.25 [0.01; 5.58]
0.24 [0.10 ; 0.58 ] EORTC 18071, 2015, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 (REV), MDX010 Ipi vs gp100, 2010 3 0% 1,719 low not evaluable Rash AE (grade 3-4)detailed results EORTC 18071, 2015 0.06 [0.03; 0.15]
0.06 [0.03 ; 0.15 ] EORTC 18071, 2015 1 0% 945 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-25 10:28 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 329,558
